SCN IS READY TO START A CLINICAL STUDY ON KI AND KS
(NGM:SCN)
The ethical committee at the Karolinska University Hospital in Sweden has approved a clinical study on SCN’s product Membraseven. The study will focus on dry mouth and dry mucous membranes.
Dryness in the mouth (Xerostomia) is a very common adverse effect when using pharmaceuticals, and it is also a part of the ageing process and common when suffering from certain diseases. Besides being uncomfortable, having a dry mouth also increases the risk for dental caries and infections in the mouth, and it also affects the quality of life by making it difficult to speak, and to chew and swallow food.
Membraseven is the trade name for the substance SCN-KI3679, which is a standardized omega fatty acid complex with a high ratio of the fatty acid omega-7. The substance is derived from sea buckthorn berries, which have been used in Asia for hundreds of years to relieve skin diagnoses and mucous membrane problems. The effects have been confirmed by modern research in Finland.
However, specific studies on saliva secretion and mucous membranes in the mouth are still needed, and therefore SCN has decided to initiate a double-blind crossover study on patients suffering from dry mouth together with scientists at the Karolinska University Hospital and Karolinska Institutet.
”Xerostomia is a common problem also for practicing dentists, especially considering that the patients are getting older and older, and that many people use pharmaceuticals with dry mouth as an adverse effect. To be able to carry out a study with high scientific quality together with the Karolinska University Hospital and Karolinska Institutet is an excellent start for testing and establishing Scandinavian Clinical Nutrition’s first own product”, says Dan Edwall, Director of Research at SCN.
“Dry mouth is a very interesting field with great potential, especially since there are few products that can help those suffering from dry mucous membranes”, says Ulf Söderberg, CEO of SCN, and continues:
“Pilot studies have shown that many patients experience a relief when taking sea buckthorn based products, and we are looking forward to the results of this study.”
For more information, please contact:
Ulf Söderberg, CEO, +46 708 13 22 81 or ulf.soderberg@scnutrition.com
Dan Edwall, Director of Research, +46 707 98 80 89 or dan.edwall@scnutrition.com
Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of
nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as
CUUR, Membraseven and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination
with innovative and scientifically documented products, create the right conditions for profitable growth both in Sweden and
in the company’s export markets. The SCN share is listed for trade on NGM Nordic MTF since December 6, 2006.